AAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa -November 04, 2023 at 12:20 pm EDT
Kiora Pharmaceuticals today announced topline results of a Phase I/II clinical trial demonstrating proof-of-concept that KIO-301, the company's first-i...
Source: marketscreener.com